Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Basic Clin Pharmacol Toxicol ; 122(3): 310-316, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28990289

RESUMO

Migraine is a common disease with a high morbidity. Valproate (VP) is used as an anti-epilepsy drug in clinic. This study aimed to investigate the role of VP in nitroglycerin (NTG)-induced migraine using a mouse model. NTG was employed by intraperitoneal injection to induce a migraine model in mice. The NTG administration caused mouse head discomforts, decreased tolerance to cold or hot stimulation and increased content of nitric oxide, calcitonin gene-related peptide and neuropeptide Y in serum, which were ameliorated by intraperitoneal injection of VP. The levels of two inflammatory factors, interleukin (IL)-1ß and inducible nitric oxide synthase, in dura mater were increased by NTG treatment, while the increase was attenuated by application of VP. In addition, the phosphorylation levels of protein kinase C (PKC) α, γ, δ and ε were increased by NTG and decreased by VP. However, their total expression at the transcriptional and translational levels did not change significantly. Two substrates of PKC, cAMP-response element binding protein 1 and signal transducer and activator of transcription 1 were also phosphorylated by NTG application, and the phosphorylation level was attenuated by VP, consistent with the change of PKC informs. Together, we demonstrated that VP prevented damage due to migraine by inhibiting PKC signalling in NTG-injected mice, which may provide a basis for investigating the clinical treatment of migraine.


Assuntos
Dura-Máter/efeitos dos fármacos , Inibidores Enzimáticos/uso terapêutico , Transtornos de Enxaqueca/prevenção & controle , Fármacos Neuroprotetores/uso terapêutico , Proteína Quinase C/antagonistas & inibidores , Transdução de Sinais/efeitos dos fármacos , Ácido Valproico/uso terapêutico , Animais , Dura-Máter/enzimologia , Dura-Máter/metabolismo , Inibidores Enzimáticos/administração & dosagem , Injeções Intraperitoneais , Isoenzimas/antagonistas & inibidores , Isoenzimas/metabolismo , Masculino , Camundongos Endogâmicos C57BL , Transtornos de Enxaqueca/sangue , Transtornos de Enxaqueca/induzido quimicamente , Transtornos de Enxaqueca/metabolismo , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Neurônios/efeitos dos fármacos , Neurônios/enzimologia , Neurônios/metabolismo , Fármacos Neuroprotetores/administração & dosagem , Óxido Nítrico/agonistas , Óxido Nítrico/sangue , Doadores de Óxido Nítrico/administração & dosagem , Doadores de Óxido Nítrico/toxicidade , Nitroglicerina/administração & dosagem , Nitroglicerina/toxicidade , Fosforilação/efeitos dos fármacos , Proteína Quinase C/metabolismo , Processamento de Proteína Pós-Traducional/efeitos dos fármacos , Distribuição Aleatória , Ácido Valproico/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA